Novopyxis
Cambridge
About Novopyxis
Novopyxis is an award-winning biotechnology company dedicated to the development of therapeutics and medical devices. Novopyxis’ flagship drug was developed using in-house proprietary mathematical algorithms and has been validated across several different in vitro, ex vivo, and in vivo models. It activates a key anti-inflammatory receptor called the AT2R and is both cardioprotective and neuroprotective. Their therapeutic was recently awarded an orphan designation for "Pediatric Cardiomyopathy" from the FDA. Droplette was recently spun out from Novopyxis (www.droplette.io) and is focused on the development of a patented medical device for the delivery of large molecules, DNA/RNA, and proteins deep through skin, tissue, and cells. They are currently partnered with Leo Pharma for the development of their device for medical dermatology applications and have won several awards including the 2015 Graduate of MassCONNECT program via MassBio, 2015 Amgen Golden Ticket Winner, 2014 Mass Challenge Finalist, Winner of 2014 CASIS-Boeing Prize for Technology in Space, and Second place winner in 2015 M2D2 New Ventures Competition
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $855.9K
- Funding stage: Seed
- Last round: Seed (Jul 2017)
- Website: novopyxis.com
- Phone: 1 (617) 285-9473
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/novopyxis-96334 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.